Truist lowered the firm’s price target on Biote to $9 from $10 but keeps a Buy rating on the shares. The company’s Q4 outlook missed on supplements issues and its 2024 guidance seemed tepid, but its $8.5M acquisition of a pellet manufacturer prompts a strategy shift to vertical integration with optionality for additional wellness products, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BTMD: